0001261380-15-000033.txt : 20150618 0001261380-15-000033.hdr.sgml : 20150618 20150618184647 ACCESSION NUMBER: 0001261380-15-000033 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150617 FILED AS OF DATE: 20150618 DATE AS OF CHANGE: 20150618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IRIDEX CORP CENTRAL INDEX KEY: 0001006045 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770210467 STATE OF INCORPORATION: DE FISCAL YEAR END: 1230 BUSINESS ADDRESS: STREET 1: 1212 TERRA BELLA AVE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 6509404700 MAIL ADDRESS: STREET 1: 1212 TERRA BELLA AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Steckel Ronald CENTRAL INDEX KEY: 0001304121 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27598 FILM NUMBER: 15941095 MAIL ADDRESS: STREET 1: C/O FOXHOLLOW TECHNOLOGIES, INC. STREET 2: 740 BAY ROAD CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-06-17 0001006045 IRIDEX CORP IRIX 0001304121 Steckel Ronald 1212 TERRA BELLA AVENUE MOUNTAIN VIEW CA 94043 0 1 0 0 VP, Operations Common Stock 2015-06-17 4 M 0 625 3.856 A 30625 D Common Stock 2015-06-17 4 S 0 625 8.7674 D 30000 D Common Stock 2015-06-17 4 M 0 1041 3.99 A 31041 D Common Stock 2015-06-17 4 S 0 1041 8.7674 D 30000 D Stock Option Right to Buy 3.856 2015-06-17 4 M 0 625 0 D 2013-02-01 2017-01-01 Common Stock 625 11875 D Stock Option Right to Buy 3.99 2015-06-17 4 M 0 1041 0 D 2003-04-16 2016-04-16 Common Stock 1041 10417 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Selling Plan adopted by the reporting person on 12/5/14. The sales price reported in Column 4 of Table 1 represents the weighted average sale price of the shares sold, ranging from $8.75 to $8.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. This option was granted pursuant to IRIDEX Corporation's 2008 Equity Incentive Plan and is exempt to Rule 16b-3. The shares are subject to vesting according to the following schedule: 1/48th of the total number of shares vest each month. The shares shall vest as follows: 12/48ths of the shares shall vest 12 months after the Vesting Commencement Date and 1/48th of the shares shall vest each month thereafter. /s/ Susan Bruce, Attorney-iin-Fact 2015-06-18